| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 27, 2012Low Mortality and Heart Failure Hospitalization Sustained at 5-Years Post Implant with Medtronic CRT-D Devices
MUNICH, GERMANY – August 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a new clinical analysis of the pivotal REVERSE (Resynchronization Reverse Remodeling in Systolic...
-
Aug 24, 2012Next-Generation Technology Reinforces Safety and Efficacy While Improving Procedure Efficiency
MINNEAPOLIS – Aug. 24, 2012 – Medtronic, Inc. (NYSE:MDT) today announced that its Arctic Front Advance™ Cardiac Cryoballoon has received both U.S. Food and Drug Administration (FDA) approval...
-
Aug 23, 2012
MINNEAPOLIS - August 23, 2012 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the company's common stock. The quarterly dividend...
-
Aug 21, 2012Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...
-
Jun 21, 2012Regulatory Agency Selects Investigational Medical Device for Endovascular Treatment of Thoracic Aortic Aneurysms Involving Branch Vessel for Early Feasibility Pilot Program
MINNEAPOLIS -- June 21, 2012 -- The U.S. Food and Drug Administration (FDA) recently selected a stent graft being developed by Medtronic, Inc. (NYSE: MDT) for an early feasibility pilot program...
-
Jun 21, 2012
MINNEAPOLIS - June 21, 2012 - The board of directors of Medtronic, Inc. (NYSE: MDT) today approved a 7.2 percent increase in its cash dividend for fiscal year 2013, raising the quarterly amount to...
-
Jun 8, 2012FDA to Review World's First Insulin Pump with Threshold Suspend - Another Significant Step Toward the Artificial Pancreas
MINNEAPOLIS - June 8, 2012 -In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that it has filed the final module of its Pre-Market...
-
May 31, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 31, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs 33rd Annual...
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...
-
May 23, 2012Grant to Partners In Health creates a program within the Rwandan Ministry of Health to provide planning assistance to six low-income countries in order to improve access to NCD care
MINNEAPOLIS--(BUSINESS WIRE)--May. 23, 2012-- In a continued commitment to help reduce the global burden of noncommunicable diseases (NCDs) such as cardiovascular disease and diabetes, the...
-
May 22, 2012Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--May. 22, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported...
-
May 17, 2012Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis
PARIS--(BUSINESS WIRE)--May. 17, 2012-- Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from...
-
May 16, 2012New Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Clinical Advantages Favoring Drug-Eluting Balloons Over Uncoated Balloons and Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing...
-
May 16, 2012Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents
PARIS--(BUSINESS WIRE)--May. 16, 2012-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: MEDTRONIC IN.PACT DRUG-ELUTING...
-
May 16, 2012Closure Ends Federal Civil and Criminal Investigations of the Company
MINNEAPOLIS--(BUSINESS WIRE)--May. 16, 2012-- Medtronic, Inc. (NYSE: MDT) today announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the United States Attorney...
-
May 15, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 15, 2012-- Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to...
-
May 15, 2012With Latest Certifications, Company’s Flagship DES Has Broadest Range of Approved Indications in Europe; Study Findings Presented at EuroPCR
PARIS--(BUSINESS WIRE)--May. 15, 2012-- As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European...
-
May 11, 2012Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 11, 2012-- Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in...
-
May 10, 2012Late-Breaking Clinical Trial Validates Medtronic Proprietary Device Algorithms
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely...
-
May 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A...
-
May 8, 2012Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries
MINNEAPOLIS--(BUSINESS WIRE)--May. 8, 2012-- Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant®...
-
Apr 30, 2012Medtronic Foundation has committed nearly $1.5 million in local scholarships.
MINNEAPOLIS--(BUSINESS WIRE)--Apr. 30, 2012-- The Medtronic Foundation today announced that 18 students have been selected as 2012 Medtronic Scholars. Each will receive a four-year scholarship...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Apr 24, 2012Medical Technology Leader Ranked in Top 50 on Corporate Responsibility Magazine's 100 Best Corporate Citizens List
MINNEAPOLIS, Apr 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. is one of America's best corporate citizens, according to the rankings recently released by Corporate Responsibility magazine. Medtronic...
-
Apr 17, 2012International Research Program Will Collect and Assess Safety and Efficacy Data on IN.PACT Admiral(TM) Drug-Eluting Balloon in Treatment of Peripheral Artery Disease
MINNEAPOLIS & LONDON, Apr 17, 2012 (BUSINESS WIRE) --In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. (NYSE:...
-
Apr 16, 2012Market-Leading Medical Device for Minimally Invasive Treatment of Abdominal Aortic Aneurysms Continues to Demonstrate Strong Safety and Efficacy
MINNEAPOLIS & LONDON, Apr 16, 2012 (BUSINESS WIRE) --Bolstering confidence in endovascular repair of abdominal aortic aneurysms (AAA), Medtronic Inc. (NYSE:MDT) announced yesterday the two-year...
-
Apr 16, 2012Latest innovation offers power technology for reconstructive spine surgery
MEMPHIS, Tenn., Apr 16, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the initiation of its launch of the POWEREASE(TM) System, an innovative system of electronic instruments...
-
Apr 13, 2012First Patients Treated in Clinical Trial of Novel Medical Device Involving Interventions for Lower-Extremity Peripheral Artery Disease
MINNEAPOLIS, Apr 13, 2012 (BUSINESS WIRE) --Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc....
-
Apr 13, 2012Interactive Tool Simulates Sudden Cardiac Arrest Event; Teaches Crucial Steps in Saving a Life
MINNEAPOLIS, Apr 13, 2012 (BUSINESS WIRE) --The Medtronic Foundation's HeartRescue Project has produced an interactive, online experience, the "Save-a-Life Simulator," to promote proper and timely...
-
Apr 10, 2012Pivotal REVERSE & Landmark RAFT Clinical Trials Demonstrate Reduction in Mortality and Heart Failure Hospitalization Rates in New Patient Population
MINNEAPOLIS--(BUSINESS WIRE)--Apr. 10, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac...
-
Mar 30, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities...
-
Mar 26, 2012ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 26, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Mar 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
-
Mar 24, 2012Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes
CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
-
Mar 15, 2012Another Medtronic First in Neuromodulation in Canada
BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
-
Mar 14, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...
-
Mar 7, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 7, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Capital Global...
-
Mar 5, 2012CapSure Sense MRI™ SureScan® Passive Fixation Leads Gives Physicians More MR-Conditional Options
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 5, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing...
-
Mar 1, 2012“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October
MINNEAPOLIS--(BUSINESS WIRE)--Mar. 1, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the...
-
Feb 29, 2012World’s First Insulin Pump with Low Glucose Suspend Showed Reduces Time Spent in Low Threshold Range
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 29, 2012-- In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE...
-
Feb 23, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 23, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Citi Healthcare Conference...
-
Feb 21, 2012Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 21, 2012-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company...
-
Feb 17, 2012Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 17, 2012-- Advancing the clinical practice of interventional cardiovascular medicine, Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (
-
Feb 16, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 16, 2012-- The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.2425 per share of the Company’s common stock. The dividend...
-
Feb 13, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 13, 2012-- Medtronic, Inc. (NYSE: MDT) announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s...
-
Feb 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2012 on Tuesday, February 21,...
-
Feb 8, 2012New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 8, 2012-- Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. (NYSE:MDT) today announced the...
-
Feb 1, 2012IMPROVE HF Bridge Study Will Examine Specific Gaps in Implementation of Guideline-Recommended Treatment in Heart Failure Patients Post-Hospital Discharge
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 1, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the...
-
Jan 30, 2012New System Builds On Sprint Quattro® Lead, Adding to the Company’s Portfolio of Innovative Technologies Proven to Treat Heart Rhythm Disorders
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a...